

Press Release

Livingstone Health Commences Trading on SGX Catalist; Mid-day Share Price of 22.5 S Cents, a 12.5% Premium Above 20 S Cents Price of New Post-Consolidation Shares Issued as Part of Reverse Takeover



Directors of Livingstone Health Holdings, along with Mr Mohamed Nasser Ismail, Global Head of Equity Capital Markets, Global Sales & Origination, SGX, struck the gong at market open today to mark the trading of shares on SGX

From left to right: Mr Dax Ng, Chief Business Officer; Dr Rachel Lim, Chief Operating Officer; Mr Mohamed Nasser Ismail, Global Head of Equity Capital Markets, Global Sales & Origination, SGX; Dr Wilson Tay, Chief Executive Officer; Dr Edwin Tan, Head of Orthopaedics; Dr Sebastian Chua, Chief Medical Officer

Singapore, 8 February 2021 – Livingstone Health Holdings Limited (“**Livingstone Health**” or the “**Group**”) commenced trading today on the Singapore Exchange (“**SGX**”) Catalist, following a successful reverse takeover (“**RTO**”). The share price at mid-day (12 noon) was 22.5 S cents, a 12.5% premium above the 20 S cents price of post-consolidation shares newly issued as part of the reverse merger of the former Citicode Ltd. (“**Citicode**”).

The listing, the first on SGX so far this year, marks a new chapter of the fast-growing Singapore-based multidisciplinary healthcare specialist. The listing ceremony at SGX was attended by directors of Livingstone Health, senior corporate executives, as well as Mr Mohamed Nasser Ismail, Global Head of Equity Capital Markets of SGX.

Citicode shareholders had approved the RTO on 22 January 2021 which also involved a 500-to-1 consolidation of the share base (from 41.3 billion to 82.6 million shares) and a transfer of listing status from SGX Mainboard to the Catalist board. Trading in the shares of Livingstone Health had been voluntarily suspended since 2 February 2021 until today.

New shares issued as part of the RTO consideration were priced at S\$0.20 per Consolidated Share.

Reflecting the support for the RTO, Livingstone Health shares began trading today above the 20 S cents post-consolidation issued share price and touched a high of 23.5 S cents (17.5% higher). Total shares traded as at 12 noon were 18.72 million.

Immediately upon completion of the RTO, Livingstone Health's share base has since been enlarged from 82.6 million to approximately 315.9 million shares.

Livingstone Health has 15 doctors practising at 12 medical clinics and one medical spa located at various Singapore locations. It offers tertiary healthcare services such as aesthetics and wellness, anaesthesiology and pain management, internal medicine, orthopaedic surgery, and primary healthcare service such as family medicine, as well as other paramedical products and services including physiotherapy. It has formed a joint venture in Cambodia to provide aesthetics and wellness services, and also offers healthcare design consultancy services.

The company has outlined growth plans to tap into the fast-growing healthcare sector by exploring other healthcare-related fields to complement its multi-disciplinary approach, and regional expansion via mergers and acquisitions, joint ventures and/or partnerships.

Dr Wilson Tay, Executive Director and CEO of Livingstone Health, said: "The completion of the RTO and the first-day trading mark a major new chapter in the growth of the Group. We intend to leverage on our capital markets platform to accelerate growth and deepen our value proposition as an integrated healthcare provider in Singapore and the region,"

"On behalf of the board of directors I thank SGX, the management team, the professionals, the shareholders and the many people whose hard work, patience and support have culminated in today's first-day trading on Catalist."

Mr Mohamed Nasser Ismail, Global Head of Equity Capital Markets, SGX, said: "We are pleased to welcome the listing of homegrown Livingstone Health Holdings Limited on SGX Catalist. With Singapore's healthcare industry recognised as among the best in the world, together with SGX's connectivity in the region, we look forward to supporting Livingstone Health in its efforts to tap on the rising growth opportunities in Asia."

- End -

About Livingstone Health

Livingstone Health Holdings Limited. (“Livingstone Health” and together with its subsidiaries, the “Group”) is a Singapore-based multidisciplinary healthcare group whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine and Orthopaedic Surgery.

The name “Livingstone” is inspired by the succulent plant Lithops, also known as “living stones”. They symbolise the Group’s resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Group has 15 medical doctors practising at 12 medical clinics and one medical spa located at convenient and accessible locations throughout Singapore. In addition, the Group has also ventured into other paramedical products and services, such as physiotherapy. It has a joint venture to provide aesthetics and wellness services in Cambodia and also offers healthcare design consultancy services.

For more information, please visit: www.livingstonehealth.com.sg

Media & Investor Contact Information

WeR1 Consultants Pte Ltd

1 Raffles Place
#02-01 One Raffles Place Mall
Suite 332
Singapore 048616
Isaac Tang, livingstone@wer1.net (M: +65 9748 0688)

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (“Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Tay Sim Yee at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone (65) 6232 3210.